HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Moberg Sustains Derma Drive, Acquires Prestige Brands' New Skin

This article was originally published in The Tan Sheet & The Rose Sheet

Executive Summary

The Swedish firm pays $40m for the PediaCare and Fiber Choice brands in addition to New Skin Liquid Bandages, which are available in spray and liquid delivery and are "the main profitability contributor in the acquired portfolio," says CEO Peter Wolpert.

You may also be interested in...



In Brief: Pfizer OTC, Moberg, Atrium, C&D, Wockhardt, Herbalife

Pfizer expands European OTC business; Moberg expands in U.S. with Bayer brands; Atrium would go private in $1.1 billion deal; C&D not bearish on gummies; GMP warning for two Wockhardt facilities; and Belgian court: Herbalife not a pyramid scheme.

J&J’s Consumer Health Product Sales Slump In Comparison A Year After COVID-19 Stockpiling

Worldwide consumer health sales in January-March period were down 3.3% to $3.5bn with results off 7.4% to $1.6bn in the US and up 0.5% to $1.9bn internationally. However, excluding “COVID-19 comparison” in the year-ago period, the consumer health segment grew low-single-digits.

US House Co-signs Banking For Hemp Industry

House passes “SAFE Banking” Act sponsored by Rep. Ed Perlmutter to allow cannabis- and hemp-related businesses in states with some form of legalized marijuana to access financial services by creating protections for those institutions. Sen. Jeff Merkley introduced the same legislation in March.

Topics

Related Companies

UsernamePublicRestriction

Register

RS122999

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel